MBX Biosciences (MBX) Competitors $10.88 -0.95 (-8.03%) Closing price 04:00 PM EasternExtended Trading$10.90 +0.01 (+0.14%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends MBX vs. TVTX, IRON, WVE, IOVA, EVO, PRAX, AMPH, GLPG, AAPG, and DYNShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Travere Therapeutics (TVTX), Disc Medicine (IRON), Wave Life Sciences (WVE), Iovance Biotherapeutics (IOVA), Evotec (EVO), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Galapagos (GLPG), Ascentage Pharma Group International (AAPG), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Travere Therapeutics Disc Medicine Wave Life Sciences Iovance Biotherapeutics Evotec Praxis Precision Medicines Amphastar Pharmaceuticals Galapagos Ascentage Pharma Group International Dyne Therapeutics MBX Biosciences (NYSE:MBX) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings. Do analysts prefer MBX or TVTX? MBX Biosciences presently has a consensus price target of $37.25, indicating a potential upside of 242.37%. Travere Therapeutics has a consensus price target of $27.77, indicating a potential upside of 26.34%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Does the media prefer MBX or TVTX? In the previous week, Travere Therapeutics had 6 more articles in the media than MBX Biosciences. MarketBeat recorded 12 mentions for Travere Therapeutics and 6 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.62 beat Travere Therapeutics' score of 0.06 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Travere Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is MBX or TVTX more profitable? MBX Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -172.75%. MBX Biosciences' return on equity of 0.00% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A N/A N/A Travere Therapeutics -172.75%-537.74%-55.65% Which has preferable valuation and earnings, MBX or TVTX? MBX Biosciences has higher earnings, but lower revenue than Travere Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/AN/AN/AN/ATravere Therapeutics$203.45M8.43-$111.40M-$4.55-4.83 Does the MarketBeat Community prefer MBX or TVTX? Travere Therapeutics received 79 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 58.87% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformMBX BiosciencesOutperform Votes4100.00% Underperform VotesNo VotesTravere TherapeuticsOutperform Votes8358.87% Underperform Votes5841.13% SummaryMBX Biosciences beats Travere Therapeutics on 7 of the 11 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$363.61M$7.05B$5.80B$20.04BDividend YieldN/A2.87%4.78%3.65%P/E RatioN/A6.0926.4134.90Price / SalesN/A314.10450.1415.61Price / CashN/A67.8344.0420.85Price / BookN/A6.757.634.92Net IncomeN/A$138.11M$3.18B$1.02B7 Day Performance4.51%-1.99%-1.82%-1.05%1 Month Performance6.35%-1.51%0.22%-1.40%1 Year PerformanceN/A-3.20%17.25%13.93% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.6329 of 5 stars$10.88-8.0%$37.25+242.4%N/A$363.61MN/A0.0036Insider TradeNews CoverageTVTXTravere Therapeutics2.9887 of 5 stars$21.10-3.0%$24.00+13.7%+184.8%$1.65B$145.24M-4.64460Earnings ReportAnalyst ForecastGap DownIRONDisc Medicine1.595 of 5 stars$54.71-0.2%$88.90+62.5%-18.2%$1.63BN/A-13.7530Insider TradeNews CoverageWVEWave Life Sciences4.4057 of 5 stars$10.66-4.6%$22.22+108.5%+175.7%$1.63B$53.61M-9.60240Positive NewsGap UpIOVAIovance Biotherapeutics4.0575 of 5 stars$5.32-6.5%$22.69+326.5%-53.4%$1.62B$90.86M-3.57500EVOEvotec1.8117 of 5 stars$4.52+1.6%$5.93+31.3%-39.6%$1.60B$845.74M0.005,061PRAXPraxis Precision Medicines1.9781 of 5 stars$84.85-2.3%$149.00+75.6%+97.9%$1.58B$2.45M-8.24110AMPHAmphastar Pharmaceuticals4.4716 of 5 stars$32.21-0.5%$50.33+56.3%-40.3%$1.55B$723.55M10.741,761GLPGGalapagos0.2296 of 5 stars$22.99+0.9%$30.75+33.8%-32.2%$1.51B$260.09M0.001,123AAPGAscentage Pharma Group InternationalN/A$18.90+1.2%N/AN/A$1.49BN/A0.00600News CoverageGap UpDYNDyne Therapeutics3.0828 of 5 stars$14.48-5.8%$49.91+244.7%-38.5%$1.47BN/A-4.07100 Related Companies and Tools Related Companies Travere Therapeutics Competitors Disc Medicine Competitors Wave Life Sciences Competitors Iovance Biotherapeutics Competitors Evotec Competitors Praxis Precision Medicines Competitors Amphastar Pharmaceuticals Competitors Galapagos Competitors Ascentage Pharma Group International Competitors Dyne Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:MBX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
